Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas

NCT07602777 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07602777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07602777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas
Lead sponsor
GlaxoSmithKline
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 22, 2026
Completion date
November 23, 2029
Enrollment
64 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma